RU2019121646A - Способы и композиции для лечения легочной гипертензии и других заболеваний легких - Google Patents
Способы и композиции для лечения легочной гипертензии и других заболеваний легких Download PDFInfo
- Publication number
- RU2019121646A RU2019121646A RU2019121646A RU2019121646A RU2019121646A RU 2019121646 A RU2019121646 A RU 2019121646A RU 2019121646 A RU2019121646 A RU 2019121646A RU 2019121646 A RU2019121646 A RU 2019121646A RU 2019121646 A RU2019121646 A RU 2019121646A
- Authority
- RU
- Russia
- Prior art keywords
- vasodilator
- carrier
- subject
- pharmaceutical composition
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434185P | 2016-12-14 | 2016-12-14 | |
| US62/434,185 | 2016-12-14 | ||
| PCT/US2017/066519 WO2018112258A1 (en) | 2016-12-14 | 2017-12-14 | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019121646A true RU2019121646A (ru) | 2021-01-15 |
| RU2019121646A3 RU2019121646A3 (https=) | 2021-03-17 |
Family
ID=60888760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019121646A RU2019121646A (ru) | 2016-12-14 | 2017-12-14 | Способы и композиции для лечения легочной гипертензии и других заболеваний легких |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US10912778B2 (https=) |
| EP (2) | EP4620525A3 (https=) |
| JP (3) | JP2020502121A (https=) |
| CN (1) | CN110381951A (https=) |
| AU (3) | AU2017378409A1 (https=) |
| BR (1) | BR112019012251A2 (https=) |
| CA (1) | CA3046025A1 (https=) |
| MX (1) | MX2019006938A (https=) |
| RU (1) | RU2019121646A (https=) |
| WO (1) | WO2018112258A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2882258T3 (es) | 2012-12-21 | 2021-12-01 | Mayo Found Medical Education & Res | Métodos y materiales para tratar estenosis de la válvula aórtica calcificada |
| IL262720B2 (en) | 2016-05-05 | 2024-06-01 | Liquidia Tech Inc | Dry powder treprostinil for the treatment of pulmonary hypertension |
| MX2019006938A (es) | 2016-12-14 | 2019-09-06 | Respira Therapeutics Inc | Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon. |
| WO2018132371A2 (en) * | 2017-01-10 | 2018-07-19 | United Therapeutics Corporation | Methods and compositions for treating pulmonary hypertension |
| KR20210150495A (ko) | 2019-04-10 | 2021-12-10 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 심혈관 기능장애의 성별-의존적 치료를 위한 방법 및 재료 |
| CA3142758A1 (en) * | 2019-06-10 | 2020-12-17 | Respira Therapeutics,Inc. | Carrier-based formulations and related methods |
| CN112569210B (zh) * | 2019-09-27 | 2023-09-15 | 盈科瑞（天津）创新医药研究有限公司 | 一种吸入用马昔腾坦溶液及其制备方法 |
| CN112773898A (zh) * | 2019-11-11 | 2021-05-11 | 广州华真医药科技有限公司 | 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用 |
| CN110946826B (zh) * | 2019-12-12 | 2022-02-22 | 烟台大学 | 一种利奥西呱口服制剂及其制备方法 |
| BR112022019274A2 (pt) | 2020-03-31 | 2022-11-16 | Softhale Nv | Entrega de aerossol de pelo menos duas composições líquidas |
| US11013688B1 (en) * | 2020-05-28 | 2021-05-25 | Softhale Nv | Methods of treatment of viral diseases |
| WO2022094100A1 (en) * | 2020-10-28 | 2022-05-05 | Insmed Incorporated | Dry powder compositions of treprostinil prodrugs and methods of use thereof |
| US20250000873A1 (en) * | 2021-09-10 | 2025-01-02 | Justus-Liebig-Universitaet Giessen | Inhaled iloprost for rescue treatment and treatment as needed in pulmonary hypertension |
| WO2024249775A2 (en) * | 2023-05-31 | 2024-12-05 | Respira Therapeutics, Inc. | Methods for treatment of pulmonary hypertension |
| CN116687888A (zh) * | 2023-06-02 | 2023-09-05 | 苏州易合医药有限公司 | 伐地那非和达泊西汀复方干粉吸入制剂及其制备方法 |
| CN121714543A (zh) * | 2024-09-23 | 2026-03-24 | 上海欣药智能科技有限公司 | 一种可吸入的含可溶性鸟苷酸环化酶受体激动剂的药物组合物及其用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1493685A (en) | 1970-12-15 | 1977-11-30 | May & Baker Ltd | 8-azapurinones |
| GB1338235A (en) | 1970-12-15 | 1973-11-21 | May & Baker Ltd | Azapurinones |
| US4883810A (en) | 1976-08-17 | 1989-11-28 | Burroughs Wellcome Co. | Ethers |
| US4306075A (en) | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
| JPS58124778A (ja) | 1982-01-20 | 1983-07-25 | Toray Ind Inc | ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体 |
| DE3417638A1 (de) | 1984-05-10 | 1985-11-14 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur bestimmung geringer stoffmengen von arzneimitteln, von koerpereigenen oder anderen chemischen substanzen in biologischem material |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US6441245B1 (en) | 1997-10-24 | 2002-08-27 | United Therapeutics Corporation | Process for stereoselective synthesis of prostacyclin derivatives |
| CA2395558C (en) | 1997-11-12 | 2007-07-17 | Bayer Aktiengesellschaft | Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| US6521212B1 (en) | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
| US6943166B1 (en) | 1999-04-30 | 2005-09-13 | Lilly Icos Llc. | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
| PT1200090E (pt) | 1999-08-03 | 2013-11-25 | Icos Corp | Formulação farmacêutica à base de um beta-carbolina e seu uso para tratar a disfunção sexual. |
| US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| CN1374953A (zh) | 1999-09-16 | 2002-10-16 | 田边制药株式会社 | 含氮的6－员芳香环化合物 |
| CN1264574C (zh) | 2000-09-06 | 2006-07-19 | 田边制药株式会社 | 口服制剂 |
| IL157009A0 (en) | 2001-03-28 | 2004-02-08 | Pfizer | N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad |
| TWI316055B (https=) | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| US20040077624A1 (en) | 2002-05-23 | 2004-04-22 | Pfizer Inc. | Novel combination |
| CA2536293A1 (en) * | 2003-08-22 | 2005-03-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating copd and pulmonary hypertension |
| CA2612917A1 (en) | 2005-06-23 | 2007-01-04 | Schering Corporation | Rapidly absorbing oral formulations of pde5 inhibitors |
| CN101410119B (zh) | 2006-02-03 | 2012-03-07 | 埃科特莱茵单一股份公司 | 依前列醇制剂及其制备方法 |
| EP2026816B1 (en) | 2006-05-15 | 2018-10-24 | United Therapeutics Corporation | Treprostinil administration using a metered dose inhaler |
| CN101903324B (zh) | 2007-12-17 | 2013-07-03 | 联合治疗公司 | 一种制备Remodulin中的活性成分曲前列素的改良方法 |
| EP2237788A4 (en) | 2007-12-27 | 2013-06-05 | Aires Pharmaceuticals Inc | COMPOUNDS FOR OBTAINING AEROSOLIZED NITRITE AND NITRIC OXIDE AND USES THEREOF |
| WO2009117095A1 (en) | 2008-03-18 | 2009-09-24 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| WO2009115235A1 (en) | 2008-03-20 | 2009-09-24 | Bayer Schering Pharma Aktiengesellschaft | Pde inhibitors for the treatment of pulmonary hypertension |
| JP5764061B2 (ja) | 2008-08-13 | 2015-08-12 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | マシテンタン含有治療用組成物 |
| LT2447254T (lt) | 2009-06-26 | 2018-01-10 | Nippon Shinyaku Co., Ltd. | Kristalai |
| WO2011030351A2 (en) | 2009-09-03 | 2011-03-17 | Rubicon Research Private Limited | Taste - masked pharmaceutical compositions |
| WO2011037613A1 (en) | 2009-09-23 | 2011-03-31 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of pgi2 receptor agonists |
| ES2611187T3 (es) * | 2010-03-15 | 2017-05-05 | United Therapeutics Corporation | Tratamiento para hipertensión pulmonar |
| BR112012028153A2 (pt) | 2010-05-03 | 2018-08-07 | Tsh Biopharm Corporation Ltd | composição farmacêutica e método para o tratamento de hipertensão |
| PT2593452T (pt) | 2010-07-14 | 2017-04-24 | Novartis Ag | Compostos heterocíclicos agonistas do receptor ip |
| WO2012030645A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
| US8561609B2 (en) | 2010-12-07 | 2013-10-22 | Respira Therapeutics, Inc. | Dry powder inhaler |
| US10463815B2 (en) | 2012-02-21 | 2019-11-05 | Respira Therapeutics, Inc. | Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents |
| WO2014067699A1 (en) | 2012-10-31 | 2014-05-08 | Activaero Gmbh | Administration of aerosolised iloprost |
| US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| WO2015127258A2 (en) | 2014-02-21 | 2015-08-27 | Respira Therapeutics, Inc. | Powder inhaler, system and methods |
| CN107427698A (zh) * | 2015-01-13 | 2017-12-01 | 维瓦斯公司 | 肺高血压的组合疗法 |
| MX2019006938A (es) | 2016-12-14 | 2019-09-06 | Respira Therapeutics Inc | Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon. |
-
2017
- 2017-12-14 MX MX2019006938A patent/MX2019006938A/es unknown
- 2017-12-14 RU RU2019121646A patent/RU2019121646A/ru unknown
- 2017-12-14 AU AU2017378409A patent/AU2017378409A1/en not_active Abandoned
- 2017-12-14 JP JP2019531750A patent/JP2020502121A/ja active Pending
- 2017-12-14 BR BR112019012251-6A patent/BR112019012251A2/pt unknown
- 2017-12-14 CA CA3046025A patent/CA3046025A1/en active Pending
- 2017-12-14 WO PCT/US2017/066519 patent/WO2018112258A1/en not_active Ceased
- 2017-12-14 EP EP25178206.6A patent/EP4620525A3/en active Pending
- 2017-12-14 US US16/469,524 patent/US10912778B2/en active Active
- 2017-12-14 CN CN201780086527.2A patent/CN110381951A/zh active Pending
- 2017-12-14 EP EP17823002.5A patent/EP3554507A1/en not_active Ceased
-
2021
- 2021-01-11 US US17/146,173 patent/US11491160B2/en active Active
- 2021-11-23 US US17/534,282 patent/US11491161B2/en active Active
-
2022
- 2022-06-29 US US17/853,005 patent/US12263174B2/en active Active
- 2022-10-17 AU AU2022256085A patent/AU2022256085A1/en not_active Abandoned
- 2022-12-09 JP JP2022197348A patent/JP2023036678A/ja active Pending
-
2025
- 2025-02-10 JP JP2025019782A patent/JP2025065408A/ja active Pending
- 2025-02-26 US US19/064,180 patent/US20250195531A1/en active Pending
- 2025-11-03 AU AU2025260006A patent/AU2025260006A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019121646A3 (https=) | 2021-03-17 |
| WO2018112258A1 (en) | 2018-06-21 |
| EP4620525A3 (en) | 2025-12-03 |
| US20210205318A1 (en) | 2021-07-08 |
| JP2025065408A (ja) | 2025-04-17 |
| US11491160B2 (en) | 2022-11-08 |
| US20250195531A1 (en) | 2025-06-19 |
| MX2019006938A (es) | 2019-09-06 |
| US20220347183A1 (en) | 2022-11-03 |
| BR112019012251A2 (pt) | 2019-11-05 |
| AU2025260006A1 (en) | 2025-11-20 |
| JP2023036678A (ja) | 2023-03-14 |
| US11491161B2 (en) | 2022-11-08 |
| CA3046025A1 (en) | 2018-06-21 |
| EP4620525A2 (en) | 2025-09-24 |
| US12263174B2 (en) | 2025-04-01 |
| AU2022256085A1 (en) | 2022-11-17 |
| AU2017378409A1 (en) | 2019-07-04 |
| EP3554507A1 (en) | 2019-10-23 |
| US20200093830A1 (en) | 2020-03-26 |
| US10912778B2 (en) | 2021-02-09 |
| CN110381951A (zh) | 2019-10-25 |
| JP2020502121A (ja) | 2020-01-23 |
| US20220079949A1 (en) | 2022-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019121646A (ru) | Способы и композиции для лечения легочной гипертензии и других заболеваний легких | |
| JP2020502121A5 (https=) | ||
| JP6669808B2 (ja) | 超低密度肺粉剤 | |
| JP2023036678A5 (https=) | ||
| CN1972730A (zh) | 格隆溴铵用于治疗儿童哮喘 | |
| TW201249442A (en) | Administration of iloprost as aerosol bolus | |
| JP2025038163A (ja) | 肺線維症を処置するための方法及び組成物 | |
| CA2888994C (en) | Levodopa formulations for rapid relief of parkinson's disease | |
| EP2957553A1 (en) | Pharmaceutical formulations of vilanterol | |
| EP2957552B1 (en) | Vilanterol formulations | |
| EP2957551B1 (en) | Dry powder formulations comprising vilanterol | |
| KR20250002714A (ko) | 폐 질환을 치료하기 위한 방법 및 조성물 | |
| WO2023154705A1 (en) | Treprostinil iloprost combination therapy | |
| HK40096956A (zh) | 治疗肺纤维化的方法和组合物 | |
| CA2888979C (en) | Reducing inter-patient variability of levodopa plasma concentrations | |
| WO2022109458A1 (en) | Imatinib formulations, manufacture, and uses thereof | |
| EP2957550A1 (en) | Pharmaceutical formulations comprising vilanterol |